Be SMART About Asthma Management: Single Maintenance and Reliever Therapy

References

1. 1.↵
   1. Reddel HK,
   2. FitzGerald JM,
   3. Bateman ED,
   4. et al

   . GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J 2019;53:1901046.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. FitzGerald JM,
   2. Tavakoli H,
   3. Lynd LD,
   4. Al Efraij K,
   5. Sadatsafavi M

   . The impact of inappropriate use of short acting beta agonists in asthma. Respir Med 2017;131:135–40.

   OpenUrlPubMed
3. 3.↵
   1. Nwaru BI,
   2. Ekström M,
   3. Hasvold P,
   4. Wiklund F,
   5. Telg G,
   6. Janson C

   . Overuse of short-acting β₂ -agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020;55:1901872.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Averell CM,
   2. Laliberté F,
   3. Germain G,
   4. et al

   . Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States. Ther Adv Respir Dis 2022;16:17534666221116997.

   OpenUrlPubMed
5. 5.↵
   Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2022 update). Available at: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf.
6. 6.↵
   1. Cloutier MM,
   2. Baptist AP,
   3. Blake KV

   , Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)et al. 2020 focused updates to the asthma management guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020;146:1217–70.

   OpenUrlCrossRef
7. 7.↵
   1. Reddel HK,
   2. Bateman ED,
   3. Schatz M,
   4. Krishnan JA,
   5. Cloutier MM

   . A practical guide to implementing SMART in asthma management. J Allergy Clin Immunol Pract 2022;10:S31–S38.

   OpenUrl
8. 8.↵
   Budesonide and formoterol fumarate dihydrate aerosol. Package Insert. AstraZeneca Pharmaceuticals LP. Published July 24, 2019. Accessed January 25, 2023. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1d266fe8-52e3-4f85-a037-c5c1afa15e60.
9. 9.↵
   1. Barnes PJ

   . Inhaled corticosteroids. Pharmaceuticals (Basel) 2010;3:514–40.

   OpenUrlPubMed
10. 10.↵
    1. Sobieraj DM,
    2. Weeda ER,
    3. Nguyen E,
    4. et al

    . Association of inhaled corticosteroids and long-acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA 2018;319:1485–96.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. O'Byrne PM,
    2. FitzGerald JM,
    3. Bateman ED,
    4. et al

    . Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med 2018;378:1865–76.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Bateman ED,
    2. Reddel HK,
    3. O'Byrne PM,
    4. et al

    . As-needed budesonide–formoterol versus maintenance budesonide in mild Asthma. N Engl J Med 2018;378:1877–87.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Beasley R,
    2. Holliday M,
    3. Reddel HK

    , Novel START Study Teamet al. Controlled trial of budesonide–formoterol as needed for mild Asthma. N Engl J Med 2019;380:2020–30.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Hardy J,
    2. Baggott C,
    3. Fingleton J

    , PRACTICAL study teamet al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet Lond Lancet 2019;394:919–28.

    OpenUrl
15. 15.↵
    1. Sovani MP,
    2. Whale CI,
    3. Oborne J,
    4. et al

    . Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br J Gen Pract J Pract 2008;58:37–43.

    OpenUrl
16. 16.↵
    1. Bisgaard H,
    2. Le Roux P,
    3. Bjåmer D,
    4. Dymek A,
    5. Vermeulen JH,
    6. Hultquist C

    . Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006;130:1733–43.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Chapman KR,
    2. Barnes NC,
    3. Greening AP,
    4. Jones PW,
    5. Pedersen S

    . Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 2010;65:747–52.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2019 Update). Available at: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf.
19. 19.↵
    1. Papi A,
    2. Corradi M,
    3. Pigeon-Francisco C,
    4. et al

    . Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013;1:23–31.

    OpenUrlPubMed
20. 20.↵
    1. Mauer Y,
    2. Taliercio RM

    . Managing adult asthma: the 2019 GINA guidelines. Cleve Clin J Med 2020;87:569–75.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Patel M,
    2. Pilcher J,
    3. Pritchard A

    , SMART Study Groupet al. Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med . 2013;1:32–42.

    OpenUrlPubMed
22. 22.↵
    1. Lazarinis N,
    2. Jørgensen L,
    3. Ekström T,
    4. et al

    . Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax 2014;69:130–6.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Fouka E,
    2. Papaioannou AI,
    3. Hillas G,
    4. Steiropoulos P

    . Asthma-COPD overlap syndrome: recent insights and unanswered questions. J Pers Med 2022;12:708.

    OpenUrlPubMed
24. 24.↵
    1. Gershon AS,
    2. Campitelli MA,
    3. Croxford R,
    4. et al

    . Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014;312:1114–21.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Kendzerska T,
    2. Aaron SD,
    3. To T,
    4. et al

    . Effectiveness and Safety of inhaled corticosteroids in older individuals with chronic obstructive pulmonary disease and/or Asthma. A Population Study. Ann Am Thorac Soc 2019;16:1252–62.

    OpenUrlPubMed
26. 26.↵
    1. Pate CA,
    2. Zahran HS,
    3. Qin X,
    4. Johnson C,
    5. Hummelman E,
    6. Malilay J

    . Asthma surveillance—United States, 2006–2018. MMWR Surveill Summ 2021;70:1–32.

    OpenUrlCrossRef
27. 27.↵
    1. Nalin U,
    2. Stout S,
    3. Portnoy JM

    . Single inhaler maintenance and reliever therapy in pediatric asthma. Curr Opin Allergy Clin Immunol 2019;19:111–7.

    OpenUrlPubMed
28. 28.↵
    1. Pollack M,
    2. Gandhi H,
    3. Tkacz J,
    4. Lanz M,
    5. Lugogo N,
    6. Gilbert I

    . The use of short-acting bronchodilators and cost burden of asthma across global initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population. J Manag Care Spec Pharm 2022;28:881–91.

    OpenUrlPubMed
29. 29.↵
    1. Rodríguez-Martínez CE,
    2. Sossa-Briceño MP,
    3. Nino G

    . Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: a cost-utility analysis in Colombia. J Allergy Clin Immunol Pract 2021;9:3816–8.e2.

    OpenUrlPubMed
30. 30.↵
    1. Gibson PG,
    2. Powell H

    . Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59:94–9.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Papi A,
    2. Chipps BE,
    3. Beasley R,
    4. et al

    . Albuterol–budesonide fixed-dose combination rescue inhaler for Asthma. N Engl J Med 2022;386:2071–83.

    OpenUrlPubMed
32. 32.↵
    A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (DENALI). Clinicaltrials.gov. Published October 7, 2022. Accessed March 6, 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT03847896.
33. 33.↵
    Allergy & Asthma Network. My Asthma Action Plan For Single Inhaler Maintenance and Reliever Therapy (SMART) with budesonide/formoterol. Accessed February 2, 2023. https://allergyasthmanetwork.org/images/Asthma/SMART_Action_Plan_Dec2022.pdf.